The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Real-time continuous glucose monitoring (RT-CGM) improves hemoglobin A1c (A1C) and hypoglycemia in people with type 1 diabetes mellitus and those with type 2 diabetes mellitus (T2DM) on prandial insulin; however, it has not been tested in people with T2DM not taking prandial insulin. We evaluated the utility of RT-CGM in people with T2DM on a variety of treatment modalities except prandial insulin. Methods: We conducted a prospective, 52-week, two-arm, randomized trial comparing RT-CGM ( n = 50) versus self-monitoring of blood glucose (SMBG) ( n = 50) in people with T2DM not taking prandial insulin. Real-time continuous glucose monitoring was used for four 2-week cycles (2 weeks on/1 week off). All patients were managed by their usual provider. This article reports on changes in A1C 0–12 weeks. Results: Mean (±standard deviation) decline in A1C at 12 weeks was 1.0% (±1.1%) in the RT-CGM group and 0.5% (±0.8%) in the SMBG group ( p = .006). There were no group differences in the net change in number or dosage of hypoglycemic medications. Those who used the RT-CGM for ±48 days (per protocol) reduced their A1C by 1.2% (±1.1%) versus 0.6% (±1.1%) in those who used it <48 days ( p = .003). Multiple regression analyses statistically adjusting for baseline A1C, an indicator for usage, and known confounders confirmed the observed differences between treatment groups were robust ( p = .009). There was no improvement in weight or blood pressure. Conclusions: Real-time continuous glucose monitoring significantly improves A1C compared with SMBG in patients with T2DM not taking prandial insulin. This technology might benefit a wider population of people with diabetes than previously thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, CGM use has been reported to reduce fear of hypoglycemia and increase confidence in avoiding/treating hypoglycemia.156,174,175”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [175]
In the citing paper
“Fonda and colleagues 59 reported on the cost‐effectiveness of the periodic rtCGM intervention previously reported by Ehrhardt et al. 33 Based on 2011 pricing, they found that intermittent rtCGM was a cost‐effective option, with incremental cost‐effectiveness ratios of $9319 and $13 030 per (life year) LY and (quality‐adjusted life year) QALY gained, substantially lower than typical ‘willingness‐to”
In the citing paper
“Randomized controlled trials of the use of rt-CGM, compared with standard blood glucose monitoring, in adults with type 2 diabetes have generally shown reductions in HbA 1c with no significant change in time in hypoglycemia (169-172).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [170]
In the citing paper
“RCT data on rtCGM use in individuals with type 2 diabetes on MDI (59), mixed therapies (10, 60), and basal insulin (61,62) have consistently shown reductions in A1C levels and increases in TIR (70-180 mg/dL [3.9-10 mmol/L]) but not a reduction in rates of hypoglycemia (63).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [60]
In the citing paper
“In these RCTs, people with type 2 diabetes not on intensive insulin therapy used CGM intermittently compared with those randomized to BGM.Both early (60) and late improvements in A1C levels were found (60,73).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [60]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
(2004) · Choice Reviews Online · doi:10.5860/choice.42-2265 · Cited by 1,384
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Research works printed but not linked: 1
- Towfgh A, 2008, Am J Manag Care., 14, 468
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Rodbard, D. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0417 · Cited by 737
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Metadata
- Authors
- Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A.
- Affiliations
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Vigersky, Robert A.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2011-05
- Volume
- 5
- Issue
- 3
- Pages
- 668-675
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC3192632
- OpenAlex
- W2071796315
- Semantic Scholar
- ee10abe8dc890b07dc22a377ef7bb8da317eadb2
- Cited by
- 199
- References
- 30
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 18 · 2023: 26 · 2022: 22 · 2021: 21 · 2020: 14 · 2019: 18 · 2018: 12 · 2017: 9 · 2016: 10 · 2015: 2 · 2013: 5 · 2012: 6
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- real-time continuous glucose monitoring, type 2 diabetes, glycemic control, HbA1c, self-monitoring of blood glucose, non-insulin-treated diabetes, hypoglycemia
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Male, Middle Aged, Prospective Studies, Regression Analysis, Blood Glucose Self-Monitoring, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1177/193229681100500320
- The paper
- Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011). The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229681100500320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.